Raltegravir: all 174 studies that test it

Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.RecruitingNCT04258475Phase 4
• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingNCT02140255Phase 1/2
• Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)CompletedNCT03667547Phase 4Results posted
• A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsCompletedNCT03537404Phase 1Results posted
• Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to RaltegravirCompletedNCT03374358Phase 4Results posted
• Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMCompletedNCT03311945Phase 3Results posted
• Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV InfectionCompletedNCT03205566Phase 4Results posted
• Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDYCompletedNCT03029689Phase 3Results posted
• Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based RegimenCompletedNCT02577042Phase 4Results posted
• The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)CompletedNCT02473367Phase 1Results posted
• Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune ActivationCompletedNCT02383355Phase 4Results posted
• Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedNCT02284035Phase 3Results posted
• Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedNCT02212379Phase 2Results posted
• Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedNCT02116660Phase 2Results posted
• Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to RaltegravirCompletedNCT02097108Phase 2Results posted
• Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 PatientsCompletedNCT01989910Phase 4Results posted
• Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based RegimenCompletedNCT01978743Not applicableResults posted
• A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)CompletedNCT01930045Phase 1Results posted
• Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV InfectionTerminatedNCT01854762Phase 2/3Results posted
• A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy VolunteersCompletedNCT01841593Phase 1Results posted
• The Effect of Antacids and Multivitamins on RaltegravirCompletedNCT01784302Phase 1Results posted
• Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 InfectionCompletedNCT01780831Phase 1Results posted
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
• Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TBCompletedNCT01751568Phase 1/2Results posted
• A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)CompletedNCT01717287Phase 2Results posted
• A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedNCT01641367Phase 4Results posted
• A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)CompletedNCT01622673Phase 1Results posted
• Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
• Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIVTerminatedNCT01601626Phase 2Results posted
• Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively TreatedCompletedNCT01529749Phase 4Results posted
• Bone and Body Comp: A Sub Study of the SECOND-LINE StudyCompletedNCT01513122Phase 4Results posted
• A Key Link for Transmission PreventionCompletedNCT01450189Not applicableResults posted
• A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIVTerminatedNCT01448486Phase 4Results posted
• Study of Options for Second-Line Effective Combination Therapy (SELECT)CompletedNCT01352715Phase 3Results posted
• The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of AgeCompletedNCT01335620Phase 4Results posted
• Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected PatientsCompletedNCT01332227Phase 4Results posted
• Levels of Raltegravir in the Female Genital TissueCompletedNCT01327482Not applicableResults posted
• Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected IndividualsTerminatedNCT01293123Not applicableResults posted
• Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected PatientsCompletedNCT01270802Phase 4Results posted
• Addition of Raltegravir to Established Antiretroviral Suppressive TherapyTerminatedNCT01245101Phase 4Results posted
• Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)CompletedNCT01214759Phase 4Results posted
• R5 Integrase Study in HIV-1 Naive PatientsCompletedNCT01204905Not applicableResults posted
• Atripla to Raltegravir Switch Study for CNS ToxicityCompletedNCT01195467Phase 3Results posted
• Effects of Intensive cART During Acute/Early HIV InfectionCompletedNCT01154673Phase 2/3Results posted
• Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV CoinfectionCompletedNCT01147107Phase 4Results posted
• Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced ProteinuriaCompletedNCT01044771Not applicableResults posted
• HIV Persistence and Viral ReservoirsCompletedNCT01025427Phase 4Results posted
• The Raltegravir and Ribavirin Pharmacokinetics (PK) StudyCompletedNCT00982553Phase 1Results posted
• Switch From Tenofovir to Raltegravir for Low Bone Mineral DensityCompletedNCT00939874Phase 4Results posted
• BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.CompletedNCT00931801Phase 4Results posted
• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenCompletedNCT00931463Phase 4Results posted
• Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard TherapyCompletedNCT00887653Phase 3Results posted
• Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the GutCompletedNCT00884793Not applicableResults posted
• Buprenorphine/Raltegravir Pharmacokinetic Interaction StudyCompletedNCT00858962Not applicableResults posted
• Effect of Raltegravir on Endothelial Function in HIV-Infected PatientsCompletedNCT00843713Phase 4Results posted
• Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected AdultsCompletedNCT00830804Phase 2Results posted
• Pilot Study of a Raltegravir Based NRTI Sparing RegimenCompletedNCT00814879Not applicableResults posted
• Comparative Study of Three NNRTI-Sparing HAART RegimensCompletedNCT00811954Phase 3Results posted
• An Interaction Study to Assess Drug Levels in Fasting Healthy Adult SubjectsCompletedNCT00802074Not applicableResults posted
• Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell ResponseCompletedNCT00772590Phase 4Results posted
• Phase IIB Pilot of Atazanavir + RaltegravirTerminatedNCT00768989Phase 2Results posted
• A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)CompletedNCT00764946Phase 3Results posted
• Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected PatientsCompletedNCT00762892Phase 4Results posted
• Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive PatientsCompletedNCT00752856Phase 2Results posted
• A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)TerminatedNCT00745823Phase 3Results posted
• Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and WomenCompletedNCT00745368Not applicableResults posted
• Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 InfectionCompletedNCT00734344Not applicableResults posted
• Genetic Predictors of Raltegravir Penetration Into Cerebrospinal FluidCompletedNCT00729924Phase 2/3Results posted
• Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)CompletedNCT00711009Phase 3Results posted
• Kaletra-isentress Treatment EvaluationCompletedNCT00700115Phase 4Results posted
• Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 PatientsCompletedNCT00672932Not applicableResults posted
• A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy SubjectsCompletedNCT00666705Phase 4Results posted
• Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir TherapyCompletedNCT00661960Not applicableResults posted
• Raltegravir Therapy for Women With HIV and Fat AccumulationCompletedNCT00656175Phase 2Results posted
• Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive SubjectsCompletedNCT00654147Phase 2Results posted
• Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive IndividualsTerminatedNCT00632970Phase 4Results posted
• Raltegravir Intensification in HIV-infected PatientsCompletedNCT00631449Phase 4Results posted
• Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level ViremiaCompletedNCT00618371Not applicableResults posted
• An Interaction Study to Assess Drug Levels in Healthy Adult SubjectsCompletedNCT00614991Not applicableResults posted
• MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV InfectionTerminatedNCT00614458Phase 2Results posted
• HIV Non Occupational Post-Exposure Prophylaxis (PEP)CompletedNCT00594646Phase 4Results posted
• Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
• Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected SubjectsCompletedNCT00529243Phase 3Results posted
• Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)CompletedNCT00525733Not applicableResults posted
• RAL-eve Study: Raltegravir Substitution StudyCompletedNCT00523237Not applicableResults posted
• Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral LoadCompletedNCT00515827Phase 2Results posted
• Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and AdolescentsCompletedNCT00485264Phase 1/2Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)TerminatedNCT00443729Phase 3Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)TerminatedNCT00443703Phase 3Results posted
• A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)CompletedNCT00369941Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)CompletedNCT00293267Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)CompletedNCT00293254Phase 3Results posted
• Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)CompletedNCT00105157Phase 2Results posted
• Combination Antiretroviral Therapy (cART) for PBCCompletedNCT03954327Phase 2
• Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD StudyStatus unknownNCT03732625Phase 4
• Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current RegimenTerminatedNCT03333083Phase 3
• Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500CompletedNCT02489487Phase 1
• Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)TerminatedNCT02247687Phase 3
• Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected PatientsCompletedNCT02210715Phase 4
• Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy VolunteersCompletedNCT02182375Phase 1

← Raltegravir overview